• Clinical development

IO102

IO102 is a peptide vaccine containing a 21-mer IDO-derived peptide. IO102 is currently in phase I clinical trial.

A first-in-man study has been performed in 10 melanoma patients where treatment with IO102 was combined with treatment with the checkpoint inhibitor, ipilimumab (anti-CTLA4 antibody). There were no safety concerns as no treatment-related grade 3 or 4 toxicity was reported. Four patients had disease stabilization. At first evaluation, five of the ten treated patients were in stable disease, one of which had an unconfirmed partial response.

An IO102 phase II clinical study is planned to be initiated in Q4 2017.

For detailed data, please go to: Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab

IO103

IO103 is a peptide vaccine containing an XX-mer PD-L1-derived peptide. IO103 is currently in preclinical testing.